Spots Global Cancer Trial Database for azd2014
Every month we try and update this database with for azd2014 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014 | NCT01026402 | Advanced Solid ... | AZD2014 | 18 Years - 150 Years | AstraZeneca | |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer | NCT02064608 | Prostate Cancer | AZD2014 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy | NCT03061708 | Stomach Neoplas... | AZD2014 | 18 Years - | Samsung Medical Center | |
| Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy | NCT03061708 | Stomach Neoplas... | AZD2014 | 18 Years - | Samsung Medical Center | |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | NCT02831257 | Neurofibromatos... Meningioma | AZD2014 | 18 Years - | Massachusetts General Hospital | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers | NCT02583542 | Triple-Negative... Squamous Cell L... Non-squamous Ce... Non-squamous Ce... | AZD2014 AZD6244 | 18 Years - | Queen Mary University of London | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT02780830 | Core: Relapsed ... Module 1: Non-G... | AZD2014 Ibrutinib | 18 Years - 130 Years | AstraZeneca | |
| AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT02780830 | Core: Relapsed ... Module 1: Non-G... | AZD2014 Ibrutinib | 18 Years - 130 Years | AstraZeneca | |
| Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies | NCT02398747 | Advanced Solid ... | AZD2014 | 20 Years - 80 Years | AstraZeneca | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas | NCT03071874 | Meningioma | AZD2014 | 18 Years - | Massachusetts General Hospital | |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas | NCT02831257 | Neurofibromatos... Meningioma | AZD2014 | 18 Years - | Massachusetts General Hospital | |
| Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer | NCT02064608 | Prostate Cancer | AZD2014 | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) | NCT02730923 | Endometrial Car... Metastatic Carc... Hormone Recepto... | AZD2014 Anastrozole | 18 Years - | Centre Leon Berard | |
| AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer | NCT01597388 | Advanced Metast... | AZD2014 Fulvestrant | 18 Years - 100 Years | AstraZeneca | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca | |
| A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer | NCT01793636 | Metastatic Clea... | AZD2014 Everolimus | 18 Years - | Queen Mary University of London | |
| A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer | NCT01793636 | Metastatic Clea... | AZD2014 Everolimus | 18 Years - | Queen Mary University of London | |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | NCT02546661 | Muscle Invasive... | AZD4547 MEDI4736 Olaparib AZD1775 Vistusertib AZD9150 Selumetinib | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
